Who is sponsoring NCT03542214?

NCT03542214 is sponsored by Zealand University Hospital.

What drugs are being tested in NCT03542214?

Interventions in NCT03542214: Calcium electroporation.

What condition does NCT03542214 study?

NCT03542214 studies Colorectal Cancer Stage IV.

Is NCT03542214 still recruiting?

NCT03542214 is currently completed. Last updated 25 February 2021.

Last reviewed 2021-02-25 · How we verify

NCT03542214

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Calcium Electroporation for the Treatment of Colorectal Cancer

Completed Phase 1 Last updated 25 February 2021

What this trial tests

Phase 1 trial testing Calcium electroporation in Colorectal Cancer Stage IV in 6 participants. Completed in 1 January 2021.

Timeline

24 April 2018

Primary endpoint
1 October 2020

1 January 2021

Quick facts

Lead sponsor	Zealand University Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	6
Start date	24 April 2018
Primary completion	1 October 2020
Estimated completion	1 January 2021
Sites	1 location across Denmark

Drugs / interventions tested

Calcium electroporation — full drug profile →

Conditions studied

Colorectal Cancer Stage IV — all drugs for Colorectal Cancer Stage IV →

Sponsor

Zealand University Hospital

Who can join

18 and older, any sex, with Colorectal Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this phase I study 6 patients with inoperable colorectal cancer is treated with calcium electroporation to establish safety and efficacy of the treatment.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

A Comprehensive Review of Calcium Electroporation -A Novel Cancer Treatment Modality.
Frandsen SK, Vissing M, Gehl J. · · 2020 · cited 82× · PMID 31991784 · DOI 10.3390/cancers12020290
The Impact of Calcium Overload on Cellular Processes: Exploring Calcicoptosis and Its Therapeutic Potential in Cancer.
Gielecińska A, Kciuk M, Kontek R. · · 2024 · cited 23× · PMID 39769488 · DOI 10.3390/ijms252413727
In Vitro Study of Calcium Microsecond Electroporation of Prostate Adenocarcinoma Cells.
Kiełbik A, Szlasa W, Michel O, Szewczyk A, et al · · 2020 · cited 16× · PMID 33227916 · DOI 10.3390/molecules25225406
Endoscopic calcium electroporation for colorectal cancer: a phase I study.
Broholm M, Vogelsang R, Bulut M, Stigaard T, et al · · 2023 · cited 14× · PMID 37180313 · DOI 10.1055/a-2033-9831
Palliative Treatment of Esophageal Cancer Using Calcium Electroporation.
Egeland C, Baeksgaard L, Gehl J, Gögenur I, et al · · 2022 · cited 14× · PMID 36358702 · DOI 10.3390/cancers14215283

Verify or expand the search:

Other trials of Calcium electroporation

Trials testing the same drug.

NCT05609656 — Electroporation and Immunotherapy in Metastatic Colorectal Cancer · Phase 2 · terminated
NCT04605419 — Calcium Electroporation in Patients With Cell Changes in the Esophagus · Phase 1 · unknown
NCT04259658 — Histopathologic Effect of Calcium Electroporation on Cancer in the Skin · Phase 2 · completed
NCT04225767 — Calcium Electroporation as a Treatment for Cutaneous and Subcutaneous Malignant Tumours · Phase 2 · unknown
NCT03694080 — Calcium Electroporation for Early Colorectal Cancer · Phase 1 · unknown

Other recruiting trials for Colorectal Cancer Stage IV

Currently open trials in the same condition.

NCT07328087 — COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer · EARLY_PHASE1 · recruiting
NCT06342401 — Early Onset Colorectal Cancer Detection · recruiting
NCT05426005 — Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer · Phase 1, PHASE2 · recruiting
NCT05576896 — Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-muta · Phase 2 · recruiting
NCT05171660 — Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer · Phase 3 · active not recruiting

Other Zealand University Hospital trials

Trials by the same sponsor.

NCT07373561 — Post-Intensive Care Syndrome and Associated Symptom Burden Among Danish ICU Survivors · not yet recruiting
NCT07386080 — Carbergoline for Antipsychotic Induced Hyperprolactinemia. · Phase 4 · not yet recruiting
NCT07482150 — The Connect Trial: Connecting Hospital Patients to Alcohol Care · NA · not yet recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07365527 — Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03542214 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zealand University Hospital
Last refreshed: 25 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03542214.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing